A Randomized, Open Label Multi-Center Study of Single Agent Larotaxel (XRP9881) Compared to Continuous Administration of 5-FU for the Treatment of Patients with Advanced Pancreatic Cancer Previously Treated with a Gemcitabine-Containing Regimen
|Effective start/end date||10/31/08 → 12/31/10|
- SANOFI-AVENTIS US
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.